Official Injection Sites for GLP-1 Medications According to their FDA-approved prescribing information, GLP-1 medications semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) are administered as injections just under the skin (subcutaneous) in three areas: Abdomen avoid the 2 inches (5 cm) directly around the navel Thigh outer/front thigh Upper arm back of the upper arm All four FDA labels (Ozempic 1 , Zepbound 2 , Mounjaro 3 , Wegovy 4 ) explicitly state that patients should rotate injection sites with each dose
Biochem Biophys Res Commun 46:849854 Oades RD, Myint AM, Dauvermann MR, Schimmelmann BG, Schwarz MJ (2010) Attention-deficit hyperactivity disorder (ADHD) and glial integrity: an exploration of associations of cytokines and kynurenine metabolites with symptoms and attention
It is not a licensed medicinal product and is not approved for human consumption or clinical administration
GLP-1 medications such as semaglutide and tirzepatide suppress appetite significantly, which reduces total food intake but also creates a risk of inadequate protein and micronutrient consumption
Daily sunscreen use, antioxidant skincare, and avoiding picking at the skin can prevent recurrence
